Research In Brief
This article was originally published in The Gray Sheet
Executive Summary
Xience v. Cypher "The unrestricted use of everolimus-eluting stents appears to be associated with improved clinical long-term outcome compared with sirolimus-eluting stents," Swiss researchers concluded from data presented Aug. 30 at the European Society of Cardiology annual conference in Stockholm. Using propensity score matching, the study retrospectively compared clinical outcomes from 1,342 pairs of patients treated with Abbott's Xience or Johnson & Johnson's Cypher. The composite endpoint of death, myocardial infarction and target vessel revascularization occurred in 14.9% of Xience patients and 18% of Cypher patients after up to three years of follow-up